

Information for **Connecticut** Prescribers of Prescription Drugs

Tyenne® (tocilizumab-aazg)

- The following information is being provided to Connecticut prescribers pursuant to Connecticut law HB 6669.
- The prices listed below represent the Wholesale Acquisition Costs ("WAC") as made available to the public by a third-party publisher. WAC does not reflect discounts, rebates and other reductions in price. The actual price paid by patients may differ and is dependent upon the individual patient's insurance.

Marketed Product	Strength	Container Size	Formulation	NDC	WAC (Package)	Package Size
Tyenne® (tocilizumab-aazg) intravenous infusion	80 mg / 4 mL (20 mg / mL)	4 mL	Liquid	65219-0590-04	\$ 391.68	1
Tyenne® (tocilizumab-aazg) intravenous infusion	200 mg / 10 mL (20 mg / mL)	10 mL	Liquid	65219-0592-10	\$ 979.20	1
Tyenne® (tocilizumab-aazg) intravenous infusion	400 mg / 20 mL (20 mg / mL)	20 mL	Liquid	65219-0594-20	\$ 1,958.40	1
Tyenne® (tocilizumab-aazg) subcutaneous injection	162 mg	0.9 mL	Liquid	65219-596-01	\$763.63	1
Tyenne® (tocilizumab-aazg) subcutaneous injection	162 mg	0.9 mL	Liquid	65219-598-10	\$763.63	1

Date: [December 22, 2025]

Tyenne® is a registered trademark of Fresenius Kabi Deutschland GmbH.
Other trademarks are the property of their respective owners.